Clarity Pharmaceuticals

Clarity Pharmaceuticals company information, Employees & Contact Information

Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.

Company Details

Employees
65
Founded
-
Address
National Innovation Centre, 4 Cornwallis Street,australia
Phone
610292094037
Email
sa****@****als.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Sydney, NSW
Looking for a particular Clarity Pharmaceuticals employee's phone or email?

Clarity Pharmaceuticals Questions

News

Clarity Pharmaceuticals Locks in Copper-67 Supply from Nusano - TechBuzz News

Clarity Pharmaceuticals Locks in Copper-67 Supply from Nusano TechBuzz News

64Cu-SAR-bisPSMA shows superior prostate cancer detection vs 68Ga-PSMA-11 PET/CT - Urology Times

64Cu-SAR-bisPSMA shows superior prostate cancer detection vs 68Ga-PSMA-11 PET/CT Urology Times

Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences - PR Newswire

Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences PR Newswire

Co-PSMA trial achieves primary endpoint - The Manila Times

Co-PSMA trial achieves primary endpoint The Manila Times

Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT - Urology Times

Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT Urology Times

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano - PR Newswire

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano PR Newswire

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase - Urology Times

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase Urology Times

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA - PR Newswire

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA PR Newswire

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC - Urology Times

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC Urology Times

Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer - PR Newswire

Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer PR Newswire

Collaboration to support phase 3 SECuRE trial of 67Cu-SAR-bisPSMA - Urology Times

Collaboration to support phase 3 SECuRE trial of 67Cu-SAR-bisPSMA Urology Times

Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA - PR Newswire

Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA PR Newswire

Head-to-head trial to compare 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT - Urology Times

Head-to-head trial to compare 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT Urology Times

Clarity signs copper-67 Supply Agreement with Nusano - PR Newswire

Clarity signs copper-67 Supply Agreement with Nusano PR Newswire

FDA fast tracks 64Cu-SAR-bisPSMA for prostate cancer imaging - Urology Times

FDA fast tracks 64Cu-SAR-bisPSMA for prostate cancer imaging Urology Times

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT - PR Newswire

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT PR Newswire

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer - Urology Times

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer Urology Times

Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences - PR Newswire

Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences PR Newswire

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx - PR Newswire

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx PR Newswire

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer - Urology Times

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer Urology Times

Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical - PR Newswire

Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical PR Newswire

FDA grants fast track designation to 67Cu-SAR-bisPSMA for mCRPC - Urology Times

FDA grants fast track designation to 67Cu-SAR-bisPSMA for mCRPC Urology Times

Clarity's theranostic prostate cancer trial advances to multi-dose phase - PR Newswire

Clarity's theranostic prostate cancer trial advances to multi-dose phase PR Newswire

FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer - Urology Times

FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer Urology Times

SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort - PR Newswire

SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort PR Newswire

64Cu-SAR-bisPSMA Bests SOC 68Ga-PSMA-11 PET/CT in Detecting PSMA-Positive Prostate Cancer Lesions - OncLive

64Cu-SAR-bisPSMA Bests SOC 68Ga-PSMA-11 PET/CT in Detecting PSMA-Positive Prostate Cancer Lesions OncLive

Phase 3 trial of 64Cu-SAR-bisPSMA in BCR of prostate cancer set to launch in 2025 - Urology Times

Phase 3 trial of 64Cu-SAR-bisPSMA in BCR of prostate cancer set to launch in 2025 Urology Times

Copper-67 SAR-bisPSMA updates - PR Newswire

Copper-67 SAR-bisPSMA updates PR Newswire

Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer - PR Newswire

Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer PR Newswire

64Cu-SAR-bisPSMA can detect small prostate cancer lesions, new data show - Urology Times

64Cu-SAR-bisPSMA can detect small prostate cancer lesions, new data show Urology Times

Phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer launches - Urology Times

Phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer launches Urology Times

PSA Undetectable in First Patient With mCRPC Given Cu-67 SAR-bisPSMA - Targeted Oncology

PSA Undetectable in First Patient With mCRPC Given Cu-67 SAR-bisPSMA Targeted Oncology

Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics - Cardinal Health

Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics Cardinal Health

Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed - PR Newswire

Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed PR Newswire

NorthStar Medical Radioisotopes Now Routinely Manufacturing High Activity Copper-67 on its Electron Accelerators for Clarity Pharmaceuticals' Therapy Clinical Programs - FinancialContent

NorthStar Medical Radioisotopes Now Routinely Manufacturing High Activity Copper-67 on its Electron Accelerators for Clarity Pharmaceuticals' Therapy Clinical Programs FinancialContent

Clarity Pharmaceuticals raises $1.1 million - ANSTO

Clarity Pharmaceuticals raises $1.1 million ANSTO

Top Clarity Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant